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Summary
Expression profiling of T24 cells revealed that 17 out of 313 human miRNAs were upregulated more than 3-fold by simul-
taneous treatment with the chromatin-modifying drugs 5-aza-20-deoxycytidine and 4-phenylbutyric acid. One of these,
miR-127, is embedded in a CpG island and is highly induced from its own promoter after treatment. miR-127 is usually ex-
pressed as part of amiRNA cluster in normal cells but not in cancer cells, suggesting that it is subject to epigenetic silencing.
In addition, the proto-oncogene BCL6, a potential target of miR-127, was translationally downregulated after treatment.
These results suggest that DNA demethylation and histone deacetylase inhibition can activate expression of miRNAs that
may act as tumor suppressors.Introduction
MicroRNAs (miRNAs) arew22 nucleotide (nt) noncoding RNAs
that can downregulate various gene products by translational
repression when partially complementary sequences are pres-
ent in the 30 untranslated regions (30 UTR) of the target mRNAs
or by directing mRNA degradation (He and Hannon, 2004).
miRNAs are expressed in a tissue-specific manner and are con-
sidered to play important roles in cell proliferation, apoptosis,
and differentiation during mammalian development (Ambros,
2004; Bartel, 2004; Sempere et al., 2004). Moreover, recent
studies have shown a link between patterns of miRNA expres-
sion and the development of cancer (Meltzer, 2005).
The profiling of miRNA expression has revealed that most of
them have lower expression levels in tumors compared to nor-
mal tissues, while some miRNAs are upregulated or unchanged
(Lu et al., 2005). Recent studies have also shown that some
miRNAs are downregulated in various human cancers, indicat-
ing that they may act as tumor suppressors (Calin et al., 2002;
Michael et al., 2003; Takamizawa et al., 2004). Indeed, let-7,
which is downregulated in lung cancers, targets a criticalCANCER CELL 9, 435–443, JUNE 2006 ª2006 ELSEVIER INC. DOI 10.10oncogene, RAS, and miR-15 and 16, which are downregulated
in chronic lymphocytic leukemias, target an antiapoptotic factor,
BCL2 (Cimmino et al., 2005; Johnson et al., 2005).
Although the biological importance ofmiRNAs is becoming in-
creasingly apparent, regulation of miRNA expression is not fully
understood. DNA methylation and histone modification play
critical roles in chromatin remodeling and general regulation of
gene expression in mammalian development and human
diseases, such as cancer (Egger et al., 2004). To investigate
whether miRNAs can be controlled by these epigenetic alter-
ations, we analyzed miRNA expression in human cancer cells
and normal fibroblasts treated with the DNA-demethylating
agent 5-aza-20-deoxycytidine (5-Aza-CdR) and/or the histone
deacetylase (HDAC) inhibitor 4-phenylbutyric acid (PBA).
Expression profiling revealed that 17 out of 313 human miRNAs
examined were upregulated more than 3-fold by simultaneous
treatment of T24 human bladder cancer cells with 5-Aza-CdR
and PBA. In particular, we focused on miR-127, because it is
embedded in a CpG island, and its expression was highly in-
duced by 5-Aza-CdR and PBA treatment. Recent studies with
mice have shown that miR-127 is located in a miRNA clusterS I G N I F I C A N C E
Little is known about the regulation of microRNA (miRNA) expression, although the biological importance of these noncoding RNAs is
becoming increasingly apparent. We show that a subset of miRNAs is upregulated in cancer cells by treatment with 5-aza-20-deoxy-
cytidine and 4-phenylbutyric acid, which inhibit DNAmethylation and histone deacetylase, respectively. In particular, miR-127, which
is located within a CpG island and silenced in human cancer cells, is highly induced after treatment from its own promoter with down-
regulation of its potential target, the proto-oncogene BCL6. Our study suggests that induction of somemiRNAs by epigenetic treatment
may be a novel strategy for anticancer therapy.16/j.ccr.2006.04.020 435
A R T I C L EFigure 1. Expression profiling of human miRNAs in
T24 and LD419 cells after 5-Aza-CdR and PBA
treatment
A: miRNAs upregulated over 3-fold by treatment
of T24 and LD419 cells with 5-Aza-CdR and PBA.
aA total of 313 human miRNAs were analyzed
by miRNA microarray (LC Sciences; http://
www.lcsciences.com/). bUntreated cells and
cells treated with 5-Aza-CdR (3 mM) and/or PBA
(3 mM) for 6 days were labeled with Cy3 and
Cy5, respectively. These values represent the
mean of seven redundancies on the chip for
each miRNA, while the dashes indicate that
the difference between Cy5 and Cy3 was not
significant or Cy5/Cy3 ratio was under 3.
B: Northern blot analyses of miR-127, -182, -368,
-495, and -517a in T24 and LD419 cells untreated
or treated with 5-Aza-CdR (3 mM) and PBA
(3 mM). U6 RNA expression was used as a loading
control.of an imprinted locus on mouse chromosome 12, whereas the
imprinted expression of these miRNAs has not been demon-
strated in human (Seitz et al., 2003, 2004). Although the human
miR-127 gene is located within a cluster with miR-136, miR-431,
miR-432, and miR-433 on chromosome 14q32.31 (Altuvia et al.,
2005), recent studies have revealed that miR-127 and miR-136
have different expression patterns in human cancers (Iorio
et al., 2005; Lu et al., 2005). This indicates that miR-127 and
miR-136 have different regulatory mechanisms for their expres-
sion, at least in human cancers. These findings encouraged
us to study the potential epigenetic regulation of miR-127 ex-
pression in human cancer cells. In addition, we examined the
potential correlation between miR-127 and BCL6, which is
a proto-oncogene and a predicted target of miR-127.
Results
miR-127 is located within a CpG island and is highly
induced by DNA demethylation and histone
deacetylase inhibition
miRNA microarray analysis was done on T24 human bladder
cancer cells and LD419 human normal fibroblast cells treated
with 5-Aza-CdR and/or PBA. The combination treatment with
5-Aza-CdR and PBA showed that 17 out of 313 (5.4%) human
miRNAs examined were upregulated more than 3-fold in T24436cells (Figure 1A). Normal fibroblasts (LD419 cells) also showed
more than 3-fold induction of 17 miRNAs after the treatment.
However, the pattern was quite different from those in T24 cells
(Figure 1A and data not shown). To confirm the miRNA microar-
ray data, we used Northern blot analysis of T24 and LD419 cells
before and after the treatment (Figure 1B). The Northern blot re-
sults were consistent with the microarray data for the subset of
miRNAs examined.
One of these, miR-127, is embedded in a CpG island, as de-
termined by the CpG Island Searcher Program (http://
cpgislands.usc.edu/; Takai and Jones, 2002), and was upregu-
lated 49-fold after the combination treatment with 5-Aza-CdR
and PBA but showed no significant difference with either one
of the two drugs, indicating that miR-127 can be regulated di-
rectly by the synergistic effects of DNA demethylation and his-
tone deacetylase inhibition.
miR-127 is silenced in cancer cells but is expressed
as a part of a miRNA cluster in normal fibroblasts
For further examination of the regulation of miR-127 by 5-Aza-
CdR and PBA, we extended our study to a panel of seven human
cancer cell lines (HCT116, HeLa, NCCIT, Ramos, CFPAC-1,
MCF7, and CALU-1) as well as two normal human fibroblast
cell lines (LD98 and CCD-1070Sk). Expression patterns of
miR-127 in these cell lines were analyzed by Northern blot andCANCER CELL JUNE 2006
A R T I C L EFigure 2. Expression patterns of miR-127 in can-
cer cells and normal fibroblasts treated with
5-Aza-CdR and PBA
A: Northern blot analysis of miR-127 expression
before and after treatment with different doses
of 5-Aza-CdR and PBA in a panel of cancer cell
lines (HCT116 colon carcinoma, HeLa cervical
carcinoma, NCCIT embryonic carcinoma,
Ramos lymphoma, CFPAC-1 pancreatic carci-
noma, MCF7 breast carcinoma, and CALU-1
lung carcinoma cells) and normal fibroblasts
(LD98 and CCD-1070Sk). U6 RNA expression was
used as a loading control. AP0.1, combination
of 0.1 mM 5-Aza-CdR and 1 mM PBA; AP1, combi-
nation of 1 mM 5-Aza-CdR and 1 mM PBA; AP3,
combination of 3 mM 5-Aza-CdR and 3 mM PBA.
B: Confirmation of expression patterns of miR-127
in cancer cells and normal fibroblasts treated
with 5-Aza-CdR and PBA by stem-loop RT-PCR
analyses. U6 RNA expression was used as an
internal control.stem-loop reverse transcription (RT)-PCR analyses (Chen et al.,
2005). miR-127was silenced in all the cancer cell lines examined
but was substantially induced after 5-Aza-CdR and PBA treat-
ment in a dose-dependent manner in HCT116, HeLa, NCCIT,
and Ramos cells (Figures 2A and 2B). CFPAC-1 showed only
a slight induction of miR-127 after treatment. MCF7 and
CALU-1 showed no induction of miR-127 by Northern blot anal-
yses, whereas stem-loop RT-PCR showed a slight induction,
probably due to its higher sensitivity (Figures 2A and 2B). On
the other hand, miR-127 was expressed substantially in normal
fibroblasts and was slightly upregulated after treatment (Figures
2A and 2B).
As shown in Figure 3A, miR-127 is embedded in a CpG island
and is part of a miRNA cluster with miR-136, miR-431, miR-432,
and miR-433, which shows imprinted expression in the mouse
(Seitz et al., 2003, 2004). Interestingly, the miRNA microarray
data clearly demonstrated that only miR-127 showed prominent
upregulation, while the other miRNAs in the cluster, miR-136,
-431, -432, and -433 (Figure 3A), showed no significant upregu-
lation after the combination treatment with 5-Aza-CdR and PBA.
Moreover, the Northern blot analyses also demonstrated that
neither 5-Aza-CdR nor PBA alone activated miR-127 expres-
sion, but the combination treatment with both drugs substan-
tially induced miR-127 expression in a dose-dependent manner
(Figure 3B). On the other hand, we could not detect any induc-
tion of miR-136, -431, and -433 after treatment (Figure 3B). In
contrast, all the miRNAs in the cluster (miR-127, -136, -431, -432,
and -433) were expressed in LD419 cells, as determined by the
microarray data and the Northern blot analyses (Figure 3C).CANCER CELL JUNE 2006Similar to T24 cells, only miR-127 was significantly upregulated
in LD419 cells after 5-Aza-CdR and PBA treatment, and the in-
duction of miR-127 expression was more pronounced in T24
cells than in LD419 cells. These results suggest that miR-127
is expressed as a part of the cluster in normal fibroblasts as pre-
viously observed inmice (Davis et al., 2005), whereas all miRNAs
in the cluster seem to be downregulated and/or silenced in can-
cer cells. Only miR-127 expression is inducible by 5-Aza-CdR
and PBA treatment in both normal fibroblasts and cancer cells
(see also Figure 7).
Alterations in DNA methylation and histone modification
around the promoter region of the miR-127 gene
by 5-Aza-CdR and PBA treatment
Our data obtained from the microarray and the Northern blot in-
dicate that miR-127 is induced from its own promoter after
5-Aza-CdR and PBA treatment in both LD419 and T24 cells.
Therefore, we determined the potential transcription start sites
for the primary transcripts of miR-127 after 5-Aza-CdR and
PBA treatment by 50 rapid amplification of cDNA ends (RACE;
Cai et al., 2004) in both cell lines. As shown in the diagram in
Figure 4A, we were able to identify three different start sites in
treated T24 cells and one single start site in treated LD419 cells.
Next, we examined the DNA methylation status of the pro-
moter region of the miR-127 gene before and after 5-Aza-CdR
and PBA treatment by bisulfite genomic sequencing (Figures
4A and 4B). The promoter region of the miR-127 gene was
heavily methylated in LD419 cells (97%), and the methylation
level was decreased to 81% after 5-Aza-CdR and PBA437
A R T I C L EFigure 3. Expression patterns of miRNAs in the
cluster in T24 and LD419 cells before and after
treatment with 5-Aza-CdR and PBA
A: Schematic representation of the locations of
the miRNA genes (miR-127, -136, -431, -432, and
-433) on human chromosome 14q32.31. The posi-
tions of these miRNA genes are indicated by
triangles. The miR-127 gene is embedded in a
CpG island.
B: Northern blot analyses of miR-127, -136, -431,
and -433 in T24 cells untreated or treated with
PBA and/or 5-Aza-CdR for 6 days. GAPDH
mRNA expression was used as a loading control.
P1, 1 mM PBA; A1, 1 mM 5-Aza-CdR; AP1, combi-
nation of 1 mM 5-Aza-CdR and 1 mM PBA; P3, 3
mM PBA; A3, 3 mM 5-Aza-CdR; AP3, combination
of 3 mM 5-Aza-CdR and 3 mM PBA.
C: Summary of expression patterns of miRNAs in
the cluster in LD419 and T24 cells before and after
5-Aza-CdR and PBA treatment as determined
by microarray and Northern blot analyses. aUn-
treated cells and cells treated with 5-Aza-CdR
(3 mM) and PBA (3 mM) were labeled with Cy3
and Cy5, respectively. Expression: + or 2, mean
Cy3 signal was over or under 30 for untreated
cells. Upregulation: this value represents mean
Cy5/Cy3 ratio of seven redundancies on the
chip. 2, no significant difference between Cy5 and Cy3. bExpression levels were determined by Northern blot analyses as described in Figures 1B and 3B.
ND, not determined. Expression: + or2, miRNA was visibly expressed in untreated cells or not. Upregulation: + or +++, degree of upregulation of miRNA expression
after treatment with 5-Aza-CdR (3 mM) and PBA (3 mM). 2, no observable change.treatment (Figure 4A). On the other hand, themethylation level of
the same region in T24 cells was only 60%, and it was further
decreased to 41% after treatment (Figure 4B). The high levels
of methylation in LD419 cells did not block expression of
miR-127 as a part of the cluster (see Figure 7) but were associ-
ated with low levels of induction of miR-127 after 5-Aza-CdR
and PBA treatment (Figure 3C).
Furthermore, we analyzed alterations in chromatin structure in
four regions around the transcription start sites of the miR-127
gene by chromatin immunoprecipitation (ChIP) assay and quan-
titative real-time PCR in T24 cells (Figure 4C). Both acetylated
histone H3 and methylated histone H3-lysine 4 (K4) are associ-
ated with open chromatin structure and active gene expression.
Levels of both acetylated histone H3 and methylated histone
H3-K4 were increased in T24 cells by all types of treatments
compared to untreated cells in all the regions examined
(Figure 4C). Remarkably, regions 2 and 3, which contain the
transcription start sites of miR-127, showed a pronounced in-
crease in both active marks after the high-dose combination
treatment. Moreover, we confirmed the real-time PCR data by
conventional PCR and gel analyses (Figure 4D). Both levels of
acetylated histone H3 and methylated histone H3-K4 in region
2 were increased in T24 cells by all types of treatments. These
results indicate that the induction of miR-127 after 5-Aza-CdR
and PBA treatment is accompanied by a prominent decrease
in DNA methylation levels and an increase in active histone
marks around the transcription start sites of miR-127.
miR-127 is downregulated in primary human tumors
To test whether our observations in cell lines are relevant to hu-
man cancer, we examined miR-127 expression in matched sets
of normal tissues and primary tumors of prostate, bladder, and
colon. As shown in Figure 5A, miR-127 was highly expressed in
normal prostate and bladder tissues but was remarkably down-
regulated or silenced in the corresponding tumors in all cases438examined. Normal colon tissues showed weak or no expression
of miR-127, and one case (case 1) showed downregulation in
the corresponding tumor (Figure 5A). We also examined expres-
sion levels of the other miRNAs that are adjacent to miR-127 in
the cluster, and they showed the same expression patterns as
miR-127 in the normal tissues and primary tumors (data not
shown). These results indicate that all the miRNAs in the cluster,
including miR-127, are expressed together in normal tissues
of specific organs but are downregulated or silenced in most
tumors.
Next, we analyzed DNA methylation levels in several embry-
onic and somatic tissues and primary tumors by methylation-
sensitive single-nucleotide primer extension (Ms-SNuPE) (Gon-
zalgo and Jones, 2002). The promoter region of miR-127 was
unmethylated in sperm, roughly 30% and 50% methylated in
testis and placenta, respectively, and heavily methylated in all
other human embryonic and somatic tissues examined
(Figure 5B). In addition, the prostate, bladder, and colon tissues
and the corresponding tumors that we examined for miR-127
expression in Figure 5A were also heavily methylated; there
was no significant difference between normal tissues and tu-
mors (Figure 5B). These results indicate that miR-127 can be ex-
pressed as a part of the cluster even though it is highly methyl-
ated, supporting the fact that miR-127 is processed from a large
transcript including all miRNAs in the cluster in normal tissues.
However, activation of miR-127 from its own promoter in cancer
cells is dependent on DNA demethylation and histone deacety-
lase inhibition.
Expression of BCL6, a target of miR-127, is suppressed
after 5-Aza-CdR and PBA treatment
Computational predictions for human miRNA targets show that
BCL6 is a potential target of miR-127. Detailed information is
available at Human microRNA Targets (http://www.microrna.
org/) and miRBase Targets (http://microrna.sanger.ac.uk/). ToCANCER CELL JUNE 2006
A R T I C L EFigure 4. Alterations in DNA methylation and histone modifications around the promoter region of the miR-127 gene by 5-Aza-CdR and PBA treatment
DNA methylation status of LD419 (A) and T24 (B) cells untreated or treated with 5-Aza-CdR and PBA were determined by bisulfite genomic sequencing. The bent
arrows indicate the transcription start sites of primary transcripts of miR-127 determined by 50-RACE. The vertical arrows indicate the primers used for Ms-SNuPE
analyses in Figure 5B. Each row represents a single cloned allele. Open circle, unmethylated CpG; filled circle, methylated CpG; AP3, combination of 3 mM
5-Aza-CdR and 3 mM PBA. Percentage of methylated CpG sites is shown for each analysis. C: The levels of acetylated histone H3 and trimethylated histone
H3-K4 in four regions around the miR-127 gene determined by ChIP assay in T24 cells untreated or treated with PBA and/or 5-Aza-CdR. The bent arrows indicate
the transcription start sites of primary transcript of miR-127 determined by 50-RACE. IP/Input = (immunoprecipitated DNA with each antibody 2 nonspecific
antibody control [NAC])/(input DNA 2 NAC). Values represent mean + SD of two or three experiments from two independent ChIP samples. P3, 3 mM PBA;
A3, 3 mM 5-Aza-CdR; AP1, combination of 1 mM 5-Aza-CdR and 1 mM PBA; AP3, combination of 3 mM 5-Aza-CdR and 3 mM PBA. Asterisks indicate that values
were not detectable.D:Confirmation of ChIP assay for acetylated histone H3 and methylated histone H3-K4 in region 2 by conventional PCR and gel analyses.validate that miR-127 can target BCL6, expression levels of
BCL6 in T24 cells and a lymphoma cell line, Ramos, treated
with 5-Aza-CdR and/or PBA were assessed by Western blot
analysis of nuclear protein extracts and by RT-PCR of mRNA.
Ramos cells are derived from a human B cell lymphoma and
strongly express BCL6 (Phan and Dalla-Favera, 2004). We
treated Ramos cells with 0.1 mM of 5-Aza-CdR because they
are more sensitive to this drug compared to T24 cells, which
caused a reduction of DNA methylation at the promoter region
of miR-127 from 75% to 57% (data not shown). We confirmed
that miR-127 was substantially induced by the low-dose combi-
nation treatment (Figures 2A and 2B). We found a decrease in
BCL6 protein expression in T24 and Ramos cells treated with
5-Aza-CdR and PBA (Figure 6A). On the other hand, there was
no difference in the mRNA expression levels of BCL6 before
and after treatment as examined by conventional RT-PCR
(Figure 6A) and quantitative real-time RT-PCR (data not shown),
suggesting translational inhibition of BCL6 by treatment and not
mRNA degradation. Furthermore, Ramos cells were transfected
with miR-127 precursor molecules, which are designed to di-
rectly enter the miRNA processing pathway and mimic endoge-
nous miR-127 in the cells. Overexpression of miR-127 induced
a reduction of BCL6 protein level (Figure 6B).
To further confirm target specificity between miR-127 and
BCL6, we performed a luciferase reporter assay with a vectorCANCER CELL JUNE 2006containing the putative BCL6 30 UTR target site downstream
of a luciferase reporter gene. Base pairing between miR-127
and wild-type (WT) or mutant (MUT) putative target site in the
30 UTR of BCL6 mRNA is shown in Figure 6C. These vectors
were transfected into LD419 or HeLa cells that express or
don’t express miR-127, respectively. Luciferase activity of
LD419 cells transfected with BCL6-WT was significantly lower
than LD419 cells transfected with BCL6-MUT (p = 0.0001). In
contrast, luciferase activities of HeLa cells transfected with
BCL6-WT and BCL6-MUT showed no measurable difference
(p = 0.1481; Figure 6D). These data suggest that BCL6 is one
of the targets of miR-127 and that miR-127 can downregulate
BCL6 by translational repression.
Discussion
Understanding the regulatory mechanisms controlling miRNA
expression is very important, since miRNAs can have large-
scale effects through regulation of a variety of genes during
mammalian development and carcinogenesis. Here we show,
to our knowledge for the first time, that somemiRNAs can be ac-
tivated by chromatin-modifying drugs such as inhibitors of DNA
methylation and histone deacetylation in human cancer cells.
Our microarray data indicated that a small percentage of known
miRNAs examined were upregulated by 5-Aza-CdR and PBA439
A R T I C L Etreatment in both T24 and LD419 cells. These upregulated miR-
NAs were quite different between these two cell lines, indicating
that DNA methylation status and chromatin structure around
miRNA genes are different between cancer cells and normal
fibroblasts. As shown in Figure 1B, miR-127, -368, -495, and
-517a, which were silenced in T24 cells, were highly induced
by the treatment. All of them were also highly expressed in
LD419 cells except miR-517a. In addition, a recent study pre-
dicted BCL2 as a target of miR-182 (Cimmino et al., 2005).
These results suggest that inhibitors of DNA methylation and
histone deacetylation can induce expression of some miRNAs
that may act as tumor suppressors.
In particular, we focusedour study on the induction ofmiR-127,
which is embedded within a CpG island methylated in most
tissues except sperm, and which shows imprinted expression
in the mouse (Seitz et al., 2003, 2004). In agreement with a pre-
vious study with mice (Davis et al., 2005), miR-127 is expressed
as a part of the cluster withmiR-136, -431, -432, and -433 in nor-
mal tissues and cultured fibroblasts. In contrast, the expression
of the whole cluster is downregulated or completely silenced in
primary tumors and various cancer cell lines. However, combi-
nation treatment with 5-Aza-CdR and PBA leads to a specific
Figure 5. Expression levels and DNA methylation status of miR-127 in normal
tissues and primary tumors
A: Northern blot analyses of miR-127 in matched sets of normal tissues and
primary tumors of prostate, bladder, and colon. Lower panels indicate load-
ing controls of tRNA obtained from methylene blue staining of membranes.
N, normal tissues; T, the corresponding tumors.
B: The average methylation levels of the promoter region of miR-127 in
human embryonic and somatic tissues and primary tumors determined by
Ms-SNuPE analysis. The primers used for Ms-SNuPE analysis are shown in
Figure 4A. Sp, sperm; Te, testis; Pl, placenta; Br, brain; Lu, lung; Li, liver; Ki,
kidney; Pr, prostate; Bl, bladder; Co, colon; N, normal tissues; T, the corre-
sponding tumors. The average methylation levels of four cases of prostate,
bladder, and colon tissues and the corresponding tumors that we examined
for miR-127 expression in Figure 5A are shown as mean + SD.440and prominent reactivation of miR-127 in various cancer cell
lines (Figure 7).
The synergistic effect of DNA demethylation andHDAC inhibi-
tion was investigated in greater detail by Cameron et al. and Su-
zuki et al. (Cameron et al., 1999; Suzuki et al., 2002), who
showed that silenced genes with unmethylated promoters can
often be activated by HDAC inhibitors, whereas these agents
are largely ineffective for genes with methylated promoters. In
contrast, DNA methylation inhibitors are highly effective not
only at removing cytosine methylation but also at rapidly revers-
ing chromatin structural changes (Nguyen et al., 2002). To max-
imally achieve gene reactivation, it may be necessary to simulta-
neously inhibit both DNAmethylation and histone deacetylation.
The fact that the combined effect of DNA demethylation and
HDAC inhibition could induce miR-127 expression of cancer
cells, but neither alone, suggests that the transcription of the
miR-127 gene is strongly suppressed in cancer cells.
The DNA-demethylating agent 5-Aza-CdR was effective in re-
moving cytosine methylation in the promoter region of miR-127
in both normal fibroblasts and cancer cells. The difference of
methylation levels between LD419 and T24 cells is quite inter-
esting and might be attributed to the fact that cancer cells
have a higher proliferation rate and more efficient incorporation
of 5-Aza-CdR. The decrease ofmethylation level in the promoter
region of miR-127 was higher in T24 cells (32%) compared to
LD419 cells (16%), which is consistent with the fact that the in-
duction of miR-127 expression after treatment was much higher
in T24 cells compared to LD419 cells, although induction of
miR-127 expression needs both DNA demethylation and his-
tone deacetylase inhibition.
The histone deacetylase inhibitor PBA acts to increase the
level of gene expression in combination with 5-Aza-CdR through
chromatin structural changes. ChIP assays showed that the
levels of histone H3 acetylation and H3-K4 methylation, which
are associated with active gene expression, were increased
around the transcriptional start sites of the miR-127 gene in
T24 cells treated with the high-dose combination of 5-Aza-
CdR and PBA. A previous study from our laboratory has also
shown distinct localization of histone H3 acetylation and
H3-K4 methylation to transcription start sites in the human
genome (Liang et al., 2004). These results indicate that de-
creased cytosinemethylation and increased histone H3 acetyla-
tion and H3-K4 methylation in the promoter region of the
miR-127 gene by 5-Aza-CdR and PBA treatment are associated
with its activation.
Since miR-127 is constitutively expressed in normal fibro-
blasts and normal tissues but silenced in cancer cells and down-
regulated in 9/12 (75%) primary tumors, we have focused on
a potential role of miR-127 as a tumor suppressor. The human
proto-oncogene BCL6 encodes a BTB/POZ-zinc finger tran-
scriptional repressor that is necessary for germinal center
formation and is implicated in the pathogenesis of B cell
lymphoma (Phan and Dalla-Favera, 2004; Polo et al., 2004).
Moreover, BCL6 suppresses p53 expression and modulates
DNA damage-induced apoptotic responses in germinal center
B cells (Phan and Dalla-Favera, 2004). Our results in this study
suggest that miR-127 can downregulate BCL6 by translational
repression. Thus, the induction of miR-127 expression by
5-Aza-CdR and PBA treatment in cancer cells may have an
anticancer effect through downregulation of its targets such as
BCL6. In addition, the specific induction of miR-127 is moreCANCER CELL JUNE 2006
A R T I C L EFigure 6. Identification of BCL6 as a target of
miR-127
A: Western blots of nuclear extracts sequentially
probed with antibodies against BCL6 (top panel)
and PCNA as a loading control (middle panel),
and RT-PCR analysis of BCL6mRNA in T24 and Ra-
mos cells untreated or treated with 5-Aza-CdR
and PBA. AP0.1, combination of 0.1 mM 5-Aza-
CdR and 1 mM PBA; AP3, combination of 3 mM
5-Aza-CdR and 3 mM PBA.
B: Western blots of nuclear extracts isolated from
Ramos cells transfected with miR-127 precursor
molecules (miR-127) or negative control precur-
sor miRNAs (N/C) sequentially probed with anti-
bodies against BCL6 (top panel) and PCNA as
a loading control (bottom panel).
C: Base pairing comparison between mature
miR-127 and the wild-type (WT) or mutant (MUT)
putative target site in the 30 UTR of BCL6 mRNA.
The mutant sequence is identical to the wild-
type construct except for mutations disrupting
base pairing at the 50 end of miR-127.
D: Dual luciferase assay of LD419 or HeLa cells
transfected with firefly luciferase constructs con-
taining the wild-type (WT, open bar) or mutant
(MUT, filled bar) target site of the BCL6 30 UTR for
48 hr. The firefly luciferase activity was normalized
to the Renilla luciferase activity as an internal
transfection control. Then, the luciferase values
of wild-type transfections were normalized to
the average values for the corresponding
mutant transfections. Values represent mean 6
SD of six experiments from three independent
transfections.pronounced in cancer cell lines compared to normal fibroblasts,
which might be beneficial for cancer therapy. However, as it
is possible that BCL6 expression is additionally controlled by
other miRNAs or transcriptional regulators during 5-Aza-CdR
and PBA treatment, further studies such as conditional overex-
pression models of an exogenous miR-127 in lymphoma cells
that overexpress BCL6 are needed to reveal the regulatory
mechanism of BCL6 expression.
Taken together, our results suggest an effect of epigenetic
treatment that couples inhibitors of DNA methylation and his-
tone deacetylation to induction of somemiRNAs. ThesemiRNAs
can potentially regulate expression of target genes that are im-
portant in human carcinogenesis. Further studies on epigenetic
regulation of miRNA expression are necessary, and regulation of
miRNA expression by epigenetic treatmentmay be a novel strat-
egy for prevention or treatment of human cancer.CANCER CELL JUNE 2006Experimental procedures
Cell lines
T24 (bladder transitional carcinoma cells), HCT116 (colon carcinoma cells),
NCCIT (embryonic carcinoma cells), Ramos (lymphoma cells), HeLa (cervical
carcinoma cells), CFPAC-1 (pancreatic carcinoma cells), MCF7 (breast car-
cinoma cells), CALU-1 (lung carcinoma cells), and CCD-1070Sk (human
normal fibroblast cells) were obtained from the American Type Culture Col-
lection (Rockville, MD). LD98 and LD419 (human normal fibroblast cells)
were established in our laboratory. T24, HCT116, LD98, and LD419 cells
were cultured in McCoy’s 5A medium supplemented with 10% fetal bovine
serum (FBS). NCCIT and Ramos cells were cultured in RPMI1640 medium
supplemented with 10% FBS. HeLa and MCF7 cells were cultured in MEM
medium supplemented with 10% FBS. CALU-1 was cultured in McCoy’s
5A medium supplemented with 10% FBS and 13 glutamine. CFPAC-1 cells
were cultured in IMDM medium supplemented with 10% FBS and 13 gluta-
mine. CCD-1070Sk cells were cultured in MEM medium supplemented with
10% FBS, 13 sodium pyruvate, and 13 MEM nonessential amino acids.Figure 7. A model summarizing expression
patterns of miRNAs in the cluster in normal and
cancer cells
Schematic representations of the locations of the
miRNA genes (miR-127, -136, -431, -432, and -433)
in the cluster on human chromosome 14q32.31
are shown. The miR-127 gene is embedded in
a CpG island. This locus is imprinted in the mouse.
miR-127 is expressed as a part of the cluster with
miR-136, -431, -432, and -433 in normal cells. In
contrast, the expression of the whole cluster is
downregulated or completely silenced in can-
cer cells. However, combination treatment with
5-Aza-CdR and PBA leads to a specific and
prominent reactivation of miR-127 in cancer
cells.441
A R T I C L ERNA and DNA extraction from primary tissues
Matched sets of primary prostate, bladder, and colon tumors and adjacent
normal tissues from the same patients were obtained through the USC/Norris
Tissue Procurement Core Resource after informed consent and Institutional
Review Board (IRB) approval (IRB #886005 and #926041) at the USC/Norris
Comprehensive Cancer Center. Fresh frozen blocks of tumor and corre-
sponding adjacent normal tissue identified by a pathologist were used for nu-
cleic acid extraction. RNA was extracted using the ToTALLY RNA Isolation
Kit (Ambion, Austin, TX), and DNA was isolated from the same blocks as
previously described (Wu et al., 1995).
5-Aza-CdR and PBA treatment
Cells were seeded at 5 3 105 cells per 100 mm dish 24 hr prior to treatment
with 5-Aza-CdR (1 mM or 3 mM; Sigma-Aldrich, St. Louis, MO) and/or PBA (1
mMor 3mM; Sigma-Aldrich). 5-Aza-CdRwas removed after 24 hr, while PBA
was continuously administered by replacing the medium containing PBA
every 24 hr for 5 or 6 days. Ramos cells were seeded at 2 3 106 cells per
100 mm dish 24 hr prior to treatment with 5-Aza-CdR (0.1 mM) and/or PBA
(1 mM). Treatments were done as described above for 4 days.
miRNA microarray analysis
miRNA microarray analysis was carried out by LC sciences (http://www.
lcsciences.com/; Houston, TX). In brief, poly-A tails were added to the
RNA sequences at the 30 ends using a poly(A) polymerase, and nucleotide
tags were then ligated to the poly-A tails. For each dual-sample experiment,
two sets of RNA sequences were added with tags of two different se-
quences. The tagged RNA sequences were then hybridized to the miRNA
microarray chip containing 313 humanmiRNA probes. The probe sequences
are available upon request. The labeling reaction was carried out during the
second hybridization reaction using tag-specific dendrimer Cy3 and Cy5
dyes. RNAs from untreated cells and cells treated with 5-Aza-CdR and/or
PBA were labeled with Cy3 and Cy5, respectively. The human miRNA chip
includes seven redundancies for each miRNA. The data were corrected by
subtracting the background and normalizing to the statistical median of all
detectable transcripts. Background was calculated from the median of 5%
to 25% of the lowest-intensity cells. The data normalization balances the in-
tensities of Cy3- and Cy5-labeled transcripts so that differential expression
ratios can be correctly calculated. All data were submitted to the ArrayEx-
press database, and the accession number is E-MEXP-706.
Northern blots
Total RNAwas extracted from cells with the Trizol Reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer’s instruction. Total RNA (30 mg) was
loaded onto a denaturing gel and transferred to a nylon membrane. The Star-
Fire radiolabeled probes (Integrated DNA Technologies, Coralville, IA) were
prepared by incorporation of [a-32P] dATP 6000 Ci/mmol following the man-
ufacturer’s recommendation. The sequences of the probes are available
upon request. Prehybridization and hybridization were carried out using Ex-
pressHyb Hybridization Solution (Clontech, Mountain View, CA). As a loading
control, random primed labeling probes specific for U6 RNA and GAPDH
mRNA were generated using High Prime (Roche, Indianapolis, IN).
Stem-loop RT-PCR for miRNAs
Stem-loop RT for mature miR-127 was performed as previously described
(Chen et al., 2005). All reagents for stem-loop RT were obtained from Applied
Biosystems (Foster City, CA). PCR products were analyzed on 3% agarose
gels. U6RNAwas used as an internal control. The primers used for stem-loop
RT-PCR for miR-127 are as follows: miR-127 RT, 50-GTCGTATCCAGTGC
AGGGTCCGAGGTATTCGCACTGGATACGAAGCCAA-30; miR-127 forward,
50-GCGGCTCGGATCCGTCTGAGCT-30; miR-127 reverse, 50-GTGCAGGG
TCCGAGGT-30; U6 forward, 50-CTCGCTTCGGCAGCACA-30; U6 reverse,
50-AACGCTTCACGAATTTGCGT-30.
Bisulfite genomic sequencing
Genomic DNA (2 mg) was converted with sodium bisulfite as previously de-
scribed (Frommer et al., 1992). After amplification of the bisulfite-converted
DNA with specific primers for the miR-127 gene, DNA methylation levels
were analyzed by bisulfite genomic sequencing as previously described
(Daskalakis et al., 2002).442Ms-SNuPE analysis
Genomic DNA (2 mg) was converted with sodium bisulfite as described
above. After amplification of bisulfite-converted DNA with specific primers
for the miR-127 gene, DNA methylation levels were analyzed by Ms-SNuPE
as previously described (Gonzalgo and Jones, 2002). The percentage of
methylation at each CpG site was determined by the C:T signal ratio. The
primers used for Ms-SNuPE are available upon request. A genomic DNA
panel of several human tissues was purchased from the BioChain Institute
(Hayward, CA).
ChIP assay
The ChIP assaywas performed as previously described (Nguyen et al., 2002).
Ten microliters of anti-trimethylated histone H3-K4 (Upstate Biochemistry,
Lake Placid, NY) and 10 ml of anti-acetylated histone H3 antibodies (Upstate
Biochemistry) were used. Quantitative analysis was performed by real-time
PCR with CYBR green using the DNA Engine Opticon System (MJ Research,
Waltham, MA). The specific primer sequences used for the ChIP assay are
available upon request. The fraction of immunoprecipitated DNA was calcu-
lated as follows: (immunoprecipitated DNAwith each antibody2 nonspecific
antibody control [NAC])/(input DNA 2 NAC). Signals were also confirmed by
conventional PCR and gel analyses.
Western blot with nuclear protein extracts and RT-PCR of BCL6
Nuclear protein extracts were separated by SDS/polyacrylamide gel electro-
phoresis and transferred onto a nitrocellulose membrane. Membranes were
hybridized with antibodies against BCL6 (N-3, Santa Cruz Biotechnology,
Santa Cruz, CA) and PCNA (Santa Cruz Biotechnology). Total RNA (5 mg)
was used for reverse transcription. After incubation with DNase I (Invitrogen)
to eliminate DNA contamination, Superscript III (Invitrogen) and random
hexamers (Promega, Madison, WI) were added for first strand cDNA synthe-
sis. Then PCRwas performedwith primers specific forBCL6mRNA (forward,
50-CGGAAGATGAGAGATTGCCCTGC-30; reverse, 50-GCCTGGAGGATGCA
GGCATT-30).
Transfection with miR-127 precursor molecules
miR-127 precursor molecules and negative control 1 precursormiRNAswere
purchased fromAmbion. Theywere transfected into Ramos cells at final con-
centrations of 100 nMeach using oligofectamine (Invitrogen) according to the
manufacturer’s instruction. Three days after transfection, cells were col-
lected and BCL6 expression was analyzed by Western blot as described
above.
Luciferase assay
Luciferase constructs were made by ligating oligonucleotides containing the
wild-type or mutant target site of the BCL6 30 UTR into the XbaI site of the
pGL3-control vector (Promega). LD419 or HeLa cells were transfected with
0.4 mg of firefly luciferase reporter vector containing awild-type ormutant tar-
get site and 0.02 mg of the control vector containing Renilla luciferase,
pRL-CMV (Promega), using Lipofectamine 2000 (Invitrogen) in 24-well
plates. Luciferase assays were performed 48 hr after transfection using the
Dual Luciferase Reporter Assay System (Promega). Firefly luciferase activity
was normalized to Renilla luciferase activity.
Databases and GenBank accession number
The miRNA sequences were analyzed using miRBase (http://microrna.
sanger.ac.uk/), University of California at Santa Cruz Human Genome
Browser (http://genome.cse.ucsc.edu/), and CpG Island Searcher Program
(http://cpgislands.usc.edu/; Takai and Jones, 2002). Detailed information
of base pairing comparison between miR-127 and its target site in the 30
UTR of BCL6 mRNA is available at Human microRNA Targets (http://www.
microrna.org/) and miRBase Targets (http://microrna.sanger.ac.uk/). The
GenBank accession number of BCL6 mRNA is NM_001706.
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